REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== G == GABA (Gamma-Aminobutyric Acid) The primary inhibitory neurotransmitter in the central nervous system. It reduces neuronal excitability and is involved in sleep, anxiety, and motor control. Gag reflex A protective reflex that prevents choking, triggered by stimulation of the back of the throat. It involves cranial nerves IX and X and is used to assess brainstem function. Ganglion A cluster of neuronal cell bodies located outside the central nervous system. Examples include the dorsal root ganglia and autonomic ganglia. Gap junction A direct electrical connection between adjacent neurons or glial cells formed by connexin proteins. Gap junctions allow ions and small molecules to pass rapidly between cells. Gene knockout A genetic technique used to inactivate or "knock out" a specific gene in an organism to study its function. Widely used in neuroscience to explore gene roles in brain development and behavior. Genetic predisposition An increased likelihood of developing a particular disease based on an individual's genetic makeup. In neuroscience, it is relevant to conditions like schizophrenia and Alzheimer's disease. Geniculate body A relay structure in the thalamus. The lateral geniculate body is involved in visual processing; the medial geniculate body is involved in auditory processing. Gephyrin A scaffolding protein that anchors inhibitory neurotransmitter receptors (GABA and glycine) at postsynaptic sites. Essential for synapse formation and stability. Glia Non-neuronal cells in the nervous system that support, nourish, and protect neurons.
The Moon race is often analyzed as a microcosm of the Space Race's broader dynamics. Historians such as Jennifer Frost argue that if the Space Race is measured in terms of overall spaceflight capability, the Soviet Union "won it hands down." Asif A. Siddiqi, a noted space historian, provides a more nuanced view, emphasizing the Soviet Union's dominance in smaller aspects of the race to the moon, yet critical, benchmarks such as the first lunar impact, first photos of the Moon's far side, first soft lunar landing, and first lunar orbit. These accomplishments laid the groundwork for lunar exploration, though they are often overshadowed by the Apollo 11 mission. After the period of détente, the Soviet Union managed to send 18 crafts to Venus. However, this did not generate wide speculation from the western world.Before that landing [Apollo 11], there was an enormous amount of investment in the robotic exploration of the Moon, both by the Soviets and the US, in terms of all sorts of smaller benchmarks like the first lunar impact, the first pictures of the far side of the Moon, the first soft lunar landing, and the first lunar orbit. We forget, but in those little races, the Soviet Union dominated almost every benchmark, but it is forgotten as the United States won the big one.
The heart receives nerve signals from the vagus nerve and from nerves arising from the sympathetic trunk. These nerves act to influence, but not control, the heart rate. Sympathetic nerves also influence the force of heart contraction. Signals that travel along these nerves arise from two paired cardiovascular centres in the medulla oblongata. The vagus nerve of the parasympathetic nervous system acts to decrease the heart rate, and nerves from the sympathetic trunk act to increase the heart rate. These nerves form a network of nerves that lies over the heart called the cardiac plexus. The vagus nerve is a long, wandering nerve that emerges from the brainstem and provides parasympathetic stimulation to a large number of organs in the thorax and abdomen, including the heart. The nerves from the sympathetic trunk emerge through the T1–T4 thoracic ganglia and travel to both the sinoatrial and atrioventricular nodes, as well as to the atria and ventricles. The ventricles are more richly innervated by sympathetic fibers than parasympathetic fibers. Sympathetic stimulation causes the release of the neurotransmitter norepinephrine (also known as noradrenaline) at the nerve terminals contacting the cardiac muscle cells. This shortens the repolarisation period, thus speeding the rate of depolarisation and contraction, which results in an increased heart rate. It opens chemical or ligand-gated sodium and calcium ion channels, allowing an influx of positively charged ions. Norepinephrine binds to the beta–1 receptor.
== Early peptides == The observation that the chemokine CCL2 is potentially responsible for the recruitment of macrophages to atherosclerotic lesions initiated a campaign of research into the a class of molecules that would inhibit the trafficking of leukocytes and act as a new generation of anti-inflammatory agents. ‘Peptide 3’, a dodecapeptide section of CCL2, designed as an allosteric inhibitor of MCP-1 induced leukocyte chemotaxis, was quickly shown by leukocyte migration assay to be a functional inhibitor of many chemokines in vitro with similar potency. The potency of this peptide could be increased by cyclisation and the use of the reverse sequence of D-amino acids. This peptide is called NR58-3.14.3.
Sources: en.wikipedia.org
== Research == Kratom is under preliminary research for possible antipsychotic and antidepressant properties, as well as pain management, withdrawal management, and dependence reduction. Kratom use has not been shown to positively affect mental health and shows a very small association with negative indicators (mainly externalizing disorders).
AaH I is a hemorrhagic toxin which means it causes internal bleeding by damaging blood vessels. AaH I damages the walls of capillaries, causes them to leak blood internally, leading to death. Hemorrhagic toxins are common among other snake venoms as well like rattlesnakes and the western diamondback. There are four different types of AaH in Agkistrodon acutus venom, with AaH I being the strongest hemorrhagic one. Its proteolytic activity was sensitive to pH where it was 100 times stronger in weak alkaline conditions at pH 7.5. This is referring to the break down of proteins through the enzyme proteases. Aah I has three disulfide connections at Cys117-Cys197, Cys159-Cys181 and Cys157-Cys164. There is also one calcium ion, zinc ion, and three histidine zinc ligation in the structure. Each member of the metzincins has a zinc ion in its active site. Metzincins family is metalloproteinases that use a zinc ion in the enzymatic reaction. The zinc binding in AaH I is tetrahedral, three imidazole nitrogen atoms of histidine and one oxygen atom. It is unknown whether this oxygen atom is a water molecule or a hydroxide ion. A calcium ion occurs on the surface of the AaH I molecule opposite to the active-site cleft and close to the crossover point of the N-terminal and the C-terminal segment. Its position close to the C terminus, this calcium ion in the multi-domain parent structure could well play an important role in stabilizing and tightening the segment connecting the proteolytic domain with the succeeding disintegrin domain.
Examples of devices that support DisplayPort Alternate Mode over USB-C include: MacBook, Chromebook Pixel, Surface Book 2, Samsung Galaxy Tab S4, iPad Pro (3rd generation), iPhone 15/15 Pro, HTC 10/U Ultra/U11/U12+, Huawei Mate 10/20/30, LG V20/V30/V40*/V50, OnePlus 7 and newer, ROG Phone, Samsung Galaxy S8 and newer, Nintendo Switch, Sony Xperia 1/5 etc.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.